TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFa clinical study
Resistance to immune checkpoint inhibitors (ICI) in cancer patients is not fully understood and predictive biomarkers are lacking. MELANFa (NCT03348891) is an open-label, prospective, multicenter cohort of 60 patients with advanced melanoma receiving ICI (bitherapy: ipilimumab + nivolumab; monotherapy: pembrolizumab or nivolumab). In this study we collected blood from patients taken at baseline (week0) and 6 weeks after treatment initiation (week6), isolated peripheral blood monuclear cells and assessed the impact of treatment systemic immune responses to identify potential markers of response/resistance. Overall design: CITE-seq PBMC from 8 advanced melanoma patients taken at baseline (Week 0, W0) and 6 weeks after the initiation of treatment (Week 6, W6) with nivolumab (1mg/kg) + ipilimumab (3mg/kg). Each sample was stained with 11 CITE-seq antibodies (ADT) before single cell sequencing